scholarly journals Cryobiopsy in Lung Cancer Diagnosis—A Literature Review

Medicina ◽  
2021 ◽  
Vol 57 (4) ◽  
pp. 393
Author(s):  
Mărioara Simon ◽  
Ioan Simon ◽  
Paul Andrei Tent ◽  
Doina Adina Todea ◽  
Antonia Haranguș
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Diagnostic Yield ◽  
Lung Tumors ◽  
Small Sample ◽  
Diagnostic Methods ◽  
Endobronchial Ultrasound ◽  
Forceps Biopsy ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

Optimizing the diagnosis of lung cancer represents a challenge, as well as a necessity, for improving the low survival of these patients. Flexible bronchoscopy with forceps biopsy is one of the key diagnostic procedures used for lung tumors. The small sample size and crush artifacts are several factors that can often limit access to a complete diagnosis, therefore leading to the need of repeating the bronchoscopy procedure or other invasive diagnostic methods. The bronchoscopic cryobiopsy is a recent technique that proved its utility in the diagnosis of both endobronchial and peripheral lung tumors. In comparison with conventional forceps biopsy, studies report a higher diagnostic yield and a superior quality of the collected samples for both the histopathological and the molecular diagnosis of lung cancer. This method shows promising results in sampling lung tissue, alone, or in conjunction with fluoroscopy or radial endobronchial ultrasound (r-EBUS). With a good safety and cost-benefit profile, this novel method has the potential to improve the diagnosis, and therefore the management of lung cancer patients. The objective of this narrative review is to provide a comprehensive review of the recent data regarding the advantages of cryobiopsy and r-EBUS in lung cancer diagnosis.

scholarly journals Diagnostic Value of Imaging Combined With Tumor Markers in Early Detection of Lung Cancer

2021 ◽  
Vol 8 ◽  
Author(s):  
Su-Ju Wei ◽  
Li-Ping Wang ◽  
Jun-Yan Wang ◽  
Jing-Xu Ma ◽  
Feng-Bin Chuan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Detection ◽  
Tumor Markers ◽  
Cancer Diagnosis ◽  
Diagnostic Value ◽  
Diagnostic Methods ◽  
Lung Cancer Diagnosis ◽  
Early Lung Cancer ◽  
Group A ◽  
Group B

Objective: The objective of this research is to explore the diagnostic value of imaging plus tumor markers in the early detection of lung cancer.Methods: Sixty patients with lung cancer treated in our hospital from January 2018 to January 2019 were selected as group A. They were matched with 60 patients with benign lung disease as group B and 60 healthy subjects examined in our hospital as group C. The carcino-embryonic antigen (CEA), CYFRA21-1, and neuron-specific enolase (NSE) were assessed, and the diagnostic value of tumor markers plus imaging in lung cancer diagnosis was explored.Results: The CEA, CYFRA21-1, and NSE in group A were evidently superior to those in groups B and C, and those in group B were superior to those in group C (all P < 0.001). CEA had the highest sensitivity (56.7%), and NSE had the highest specificity (93.3%). The tumor markers plus imaging had the highest sensitivity for different types of lung cancer, and the sensitivity to early lung cancer (90%) was superior to other diagnostic methods (P < 0.05).Conclusion: The tumor markers plus imaging is of great significance in early lung cancer diagnosis and provides a reference for judging the pathological classification.

scholarly journals EBUS in optimizing non-small cell lung cancer diagnosis and treatment

2020 ◽  
Author(s):  
Antonia Haranguș ◽  
Ioana Berindan-Neagoe ◽  
Lăcrămioara Toma ◽  
Ioan Șimon ◽  
Ovidiu Pop ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Molecular Analysis ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Small Cell ◽  
Endobronchial Ultrasound ◽  
Mediastinal Lymphadenopathy ◽  
Small Cell Lung ◽  
Anaplastic Lymphoma ◽  
Lung Cancer Diagnosis

Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a commonly used minimally invasive method for the diagnosis and staging of lung cancer. In order to improve its diagnostic accuracy, rapid on-site cytologic evaluation (ROSE) is being utilized in some institutions. ROSE, performed by a cytopathologist in the examination room, allows the assessment of the adequacy of the collected samples, identifies malignant cells and sometimes establishes diagnosis on the spot, thus improving diagnostic sensitivity. As non-small cell lung carcinomas (NSCLC) require not only pathological subtyping, but also molecular characterization, obtaining the adequate amount of tissue is crucial. Only a limited number of studies have analyzed the suitability of EBUS-TBNA samples for assessment of epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and programmed death-ligand 1 (PD-L1) status. Aim. We intended to examine the diagnostic yield of ROSE in NSCLC and the results and feasibility of molecular analysis performed on EBUS-TBNA small samples. Methods. 100 patients with lung tumors and hilar and/or mediastinal lymphadenopathy on CT or PET/CT scans were retrospectively identified over a 3-year period, from a prospectively maintained EBUS-TBNA database. All examinations were accompanied by on-site cytological exam - ROSE, histopathological exam (HPE) and, in the case of NSCLC, molecular testing. After the sampling of the lymph nodes, specimens were Diff-Quik stained and a rapid preliminary diagnosis was established. Immunohistochemistry and mutational testing were performed using cell blocks. Results. Adenocarcinoma was the most frequent diagnosis in both ROSE (34%) and histopathology (53%). Overall sensitivity and positive predictive value of ROSE in NSCLC, considering HPE the gold standard, were 92.18% and 93.65%, respectively, with a specificity and negative predictive value of 75% and 70.58%, respectively. All samples that were tested for EGFR mutation and ALK rearrangement were adequate for analysis. The adequacy ratio for PD-L1 was 91.66%; 37.5% of patients showed a high PD-L1 expression level, with a tumor proportion score TPS≥50%. Conclusion. EBUS-TBNA is a valuable method for lung cancer diagnosis. ROSE proved to have a moderate prediction of the final diagnosis in NSCLC. Molecular analysis of EGFR, ALK and PD-L1 can be successfully accomplished on EBUS-TBNA small tissue samples.

scholarly journals Considering Patients’ Mental Capacity When Giving Them Bad News May Help Their Well-Being: A Case of Suicide Attempt after Being Informed of Lung Cancer Diagnosis

2014 ◽  
Vol 2014 ◽  
pp. 1-4
Author(s):  
Toshiyuki Kobayashi ◽  
Satoshi Kato ◽  
Mitsuo Takeuchi
Keyword(s):  
Lung Cancer ◽  
Suicide Attempt ◽  
Cancer Diagnosis ◽  
Attempted Suicide ◽  
Well Being ◽  
Mental Capacity ◽  
Bad News ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Mental Well Being

Mental capacity is a central determinant of patients’ ability to make autonomous decisions about their care and deal with bad news. Physicians should be cognizant of this when giving patients bad news in efforts to help them to cope with the illness and to avoid a deterioration of their mental well-being. To show the importance of this concept, a case of suicide attempt with lung cancer is exemplified. A 76-year-old woman attempted suicide after receiving a diagnosis of lung cancer. Her recent life had been emotionally turbulent and she did not have sufficient mental capacity to accept and cope with this truth. She developed depression before attempting suicide.

scholarly journals The optimal sequence for bronchial brushing and forceps biopsy in lung cancer diagnosis: a random control study

2016 ◽  
Vol 8 (3) ◽  
pp. 520-526 ◽  
Author(s):  
Gang Hou ◽  
Yuan Miao ◽  
Xue-Jun Hu ◽  
Wei Wang ◽  
Qiu-Yue Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Optimal Sequence ◽  
Forceps Biopsy ◽  
Lung Cancer Diagnosis ◽  
Bronchial Brushing ◽  
Random Control ◽  
Control Study

scholarly journals Challenges in lung cancer diagnosis during the outbreak of COVID-19

2020 ◽  
Author(s):  
chunhua xu ◽  
wei wang ◽  
li li ◽  
jiwang wang
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Needle Biopsy ◽  
Transbronchial Biopsy ◽  
Public Health Emergency ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer ◽  
Novel Coronavirus ◽  
Individualized Management

A pandemic of 2019 novel coronavirus diseases (COVID-19) outbreak is a major public health emergency that has spread in the fastest speed, and caused the most extensive infection world widely. Transbronchial biopsy (TBB) and computed tomography guided percutaneous needle biopsy (CTPNB) is the most common and significant method for the diagnosis of lung cancer. During the COVID-19 pandemic, the indications of TBB and CTPNB must be managed strictly. Therefore, it is extremely indispensable to perform meticulous and individualized management for lung cancer patients to protect the patients from COVID-19.

LUNG CANCER DIAGNOSIS: NON-INVASIVE AND INVASIVE METHODS

2020 ◽  
Vol 66 (1) ◽  
pp. 42-49
Author(s):  
Andrey Arsenev ◽  
Sergey Novikov ◽  
Aleksey Barchuk ◽  
Sergey Kanaev ◽  
Anton Barchuk ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Minimally Invasive ◽  
Cancer Diagnosis ◽  
Diagnostic Techniques ◽  
Diagnostic Methods ◽  
Exhaled Breath ◽  
Non Invasive ◽  
Lung Cancer Diagnosis ◽  
Wide Range ◽  
Sensitivity Specificity

This article reviews the literature and summarizes single institution experience of applying different diagnostic algorithms for lung cancer. All diagnostic methods can be divided into three groups: non-invasive; minimally invasive and invasive. The non-invasive methods include clinical examination; imaging methods for anatomical, functional and multimodal visualization; sputum cytological, analysis of the exhaled breath, detection of various blood and sputum markers. Minimally invasive methods include endoscopy, percutaneous fine-needle and core-needle biopsy. Invasive methods include diagnostic thoracoscopy and laparoscopy, mediastinoscopy, parasternal mediastinotomy and diagnostic thoracotomy. While creating an individual diagnostic plan for each patient it is necessary to carefully analyze the effectiveness, safety, sensitivity, specificity and of different methods available among wide range of modern diagnostic techniques. Optimization of lung cancer diagnosis methods, which includes early cancer detection, is one of priority areas of modern oncology. Many aspects of this problem remain unresolved and require further research

scholarly journals Ancillary Testing in Lung Cancer Diagnosis

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
William Dubinski ◽  
Natasha B. Leighl ◽  
Ming-Sound Tsao ◽  
David M. Hwang
Keyword(s):  
Lung Cancer ◽  
Molecular Diagnostics ◽  
Cancer Diagnosis ◽  
Targeted Therapies ◽  
Patient Management ◽  
Predictive Information ◽  
Lung Cancers ◽  
Pathologic Diagnosis ◽  
Lung Cancer Diagnosis ◽  
Diagnosis Of Lung Cancer

The pathologic diagnosis of lung cancer historically has relied primarily on morphologic features of tumors in histologic sections. With the emergence of new targeted therapies, the pathologist is called upon increasingly to provide not only accurate typing of lung cancers, but also to provide prognostic and predictive information, based on a growing number of ancillary tests, that may have significant impact on patient management. This review provides an overview of ancillary tests currently used in the pathologic diagnosis of lung cancer, with a focus on immunohistochemistry and molecular diagnostics.

Sign in / Sign up

Export Citation Format

Share Document